Repository logoCyprus University of Technology
Log In(current)
Ελληνικά
English
  1. Home
  2. Cyprus University of Technology (Research Output)
  3. Άρθρα/Articles
  4. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
  • Details

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

Journal
European journal of heart failure
Date Issued
May 2018
Author(s)
Seferović, Petar M.  
Petrie, MarkC  
Filippatos, Gerasimos S.  
Anker, Stefan D.  
Rosano, Giuseppe  
Bauersachs, Johann  
Paulus, Walter J.  
Komajda, Michel  
Cosentino, Francesco  
De Boer, Rudolf A.  
Farmakis, Dimitrios  
Doehner, Wolfram  
Lambrinou, Ekaterini  
Lopatin, Yuri  
Piepoli, Massimo F.  
Theodorakis, Michael J.  
Wiggers, Henrik  
Lekakis, John  
Mebazaa, Alexandre  
Mamas, Mamas A.  
Tschöpe, Carsten  
Hoes, Arno W.  
Seferović, Jelena P.  
Logue, Jennifer  
McDonagh, Theresa  
Riley, Jillian P.  
Milinković, Ivan  
Polovina, Marija  
Van Veldhuisen, Dirk J.  
Lainscak, Mitja  
Maggioni, Aldo P.  
Ruschitzka, Frank  
McMurray, John J.V.  
DOI
10.1002/ejhf.1170
Abstract
The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30–40% of patients) and associated with a higher risk of HF hospitalization, all-cause and cardiovascular (CV) mortality. The most important causes of HF in T2DM are coronary artery disease, arterial hypertension and a direct detrimental effect of T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice versa, which emphasizes the importance of an active search for both disorders in the clinical practice. There are no specific limitations to HF treatment in T2DM. Subanalyses of trials addressing HF treatment in the general population have shown that all HF therapies are similarly effective regardless of T2DM. Concerning T2DM treatment in HF patients, most guidelines currently recommend metformin as the first-line choice. Sulphonylureas and insulin have been the traditional second- and third-line therapies although their safety in HF is equivocal. Neither glucagon-like preptide-1 (GLP-1) receptor agonists, nor dipeptidyl peptidase-4 (DPP4) inhibitors reduce the risk for HF hospitalization. Indeed, a DPP4 inhibitor, saxagliptin, has been associated with a higher risk of HF hospitalization. Thiazolidinediones (pioglitazone and rosiglitazone) are contraindicated in patients with (or at risk of) HF. In recent trials, sodium–glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have both shown a significant reduction in HF hospitalization in patients with established CV disease or at risk of CV disease. Several ongoing trials should provide an insight into the effectiveness of SGLT2 inhibitors in patients with HFrEF and HFpEF in the absence of T2DM.
Subjects

Glucose-lowering agen...

Heart failure

Heart failure hospita...

Heart failure treatme...

Type 2 diabetes melli...

File(s)
Thumbnail Image
Name

Type 2 diabetes mellitus and heart failure.pdf

Size

269.66 KB

Format

Adobe PDF

Checksum (MD5)

81e863d842e9e629092ff242cb5730d3

Explore by
  • Collections
  • Research Outputs
  • Researchers
  • Faculty & Departments
  • Theses
  • Patents
  • Projects
  • Journals
  • Conferences
Useful Links
  • Researcher Portfolio Guide
  • Researcher Profile
  • Create an ORCID ID
  • CUT Open Access Author Fund
  • ETDS Guide
Copyright Policies

Use Sherpa/Romeo to find publisher copyright policies

Go
Go
  • SPARC Author Addendum Engine
  • National Open Access Policy in Cyprus
Deposit your work to Ktisis
  • Self-archiving. Please sign in to Ktisis.
  • Email your work to:
    library.dspace@cut.ac.cy
  • Contact your subject librarian

Member of

OpenAIREre3dataOpenDOARCOREDART
Cyprus University of Technology
Library and
Information
Services

Copyright © 2022 - Library and Information Services Feedback - Built with DSpace-CRIS - 4Science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
COAR NotifyCOAR Notify